Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213544 | 0.81 | HCAR3 (0.33) | — | |
| SCHEMBL5215225 | 0.80 | PSEN1 (0.33) | ACACB | |
| SCHEMBL5212526 | 0.79 | JAK2 (0.33) | — | |
| SCHEMBL5210986 | 0.78 | P2RX3 (0.31) | — | |
| SCHEMBL279724 | 0.73 | KDM4E (0.34) | — | |
| SCHEMBL5211473 | 0.72 | KDM4E (0.33) | — | |
| SCHEMBL5133501 | 0.71 | KMT2A (0.47) | ACACBANO1CACNA1GCACNA1HCNR2 | |
| SCHEMBL2797081 | 0.67 | FAAH (0.46) | — | |
| SCHEMBL279423 | 0.66 | — | — | |
| SCHEMBL26687319 | 0.65 | NNMT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | claimed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | claimed |
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | APP, OXA1L, BACE1 | ACACB 3495/4885ANO1 1018/4885CTSS 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.